Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Nora Drove Ubreva"'
Autor:
Arndt Vogel, Christophe Borg, Vincenzo Dadduzio, Reigetsu Yoshikawa, Eric Assenat, Giovanni Brandi, Min-Hua Jen, Kenta Shinozaki, Marc Pracht, Kenta Motomura, Masatoshi Kudo, Philippe Merle, Takuji Okusaka, Jiří Tomášek, Nora Drove Ubreva, Ryan C. Widau, Richard S. Finn, Bruno Daniele, Manabu Morimoto, Andrew X. Zhu, Josep M. Llovet, Peter R. Galle
Publikováno v:
Liver International
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.2008-2020. ⟨10.1111/liv.14462⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.2008-2020. ⟨10.1111/liv.14462⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eaf2e95d78f31887f70a02125cabd9
https://pubmed.ncbi.nlm.nih.gov/32279446
https://pubmed.ncbi.nlm.nih.gov/32279446
Autor:
Rolf A. Stahel, Denis Lacombe, Fatima Cardoso, Paolo G. Casali, Anastassia Negrouk, Richard Marais, Anita Hiltbrunner, Malvika Vyas, Nathalie Varoqueaux, Claas Frohn, Patricia Cornet, Jose Amauri Soares, Nora Drove Ubreva, Michael Zaiac, Arthur Cannon, Thomas Buechele, Marika Crohns
Publikováno v:
ESMO Open
Background The academia-industry interface is important, and, despite challenges that inevitably occur, bears the potential for positive synergies to emerge. Perceived barriers to wider collaboration in academia-industry oncology research in Europe n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df21fe798f41e420c8b824f77f56c82
https://doi.org/10.1136/esmoopen-2019-000628
https://doi.org/10.1136/esmoopen-2019-000628